Arcus Biosciences (RCUS) holder to sell 10000 shares under Rule 144

Rhea-AI Filing Summary

Arcus Biosciences, Inc. is the issuer for a planned Rule 144 stock sale. A shareholder has filed to sell 10000 shares of Arcus common stock through E*TRADE Financial Corporation on the NYSE, with an aggregate market value listed as 219000 and an approximate sale date of 12/16/2025.

The shares to be sold come from 18799 restricted shares of common stock that vested on 12/15/2025, which were originally granted on 2/10/2025 by Arcus Biosciences, Inc. as compensation for services rendered. The form also includes a representation that the seller does not know of any undisclosed material adverse information about Arcus’s current or prospective operations.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	E*TRADE FINANCIAL CORPORATION 3 EDISON DRIVE ALPHARETTA GA 3005	10000	219000	122856086	12/16/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	12/15/2025	Vesting of restricted stock granted 2/10/2025	Arcus Biosciences, Inc.			18799	12/15/2025	Services rendered

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for Arcus Biosciences (RCUS) disclose?

The filing shows that a shareholder of Arcus Biosciences, Inc. (RCUS) plans to sell 10000 shares of Arcus common stock under Rule 144 on the NYSE through E*TRADE Financial Corporation.

How many Arcus Biosciences (RCUS) shares are planned to be sold and where?

The notice covers a proposed sale of 10000 shares of Arcus common stock, to be sold on the NYSE using E*TRADE Financial Corporation as broker.

What aggregate market value is associated with the planned RCUS share sale?

The Form 144 lists an aggregate market value of 219000 for the 10000 Arcus Biosciences common shares covered by the planned sale.

When were the Arcus Biosciences (RCUS) shares acquired and how?

The securities to be sold are restricted common stock that vested on 12/15/2025, originally granted on 2/10/2025 by Arcus Biosciences, Inc. in connection with services rendered.

What amount of RCUS restricted stock was acquired in the vesting event?

The table shows that 18799 shares of Arcus Biosciences common stock were acquired upon vesting of restricted stock on 12/15/2025, from Arcus Biosciences, Inc.

What representation does the seller make in the Arcus Biosciences (RCUS) Form 144?

By signing the notice, the seller represents that they do not know any material adverse information regarding Arcus Biosciences’ current or prospective operations that has not been publicly disclosed, as required by the form.